Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Consensus Target Price from Brokerages

Key Points

• Voyager Therapeutics has received a consensus rating of "Buy" from eight analysts, with seven ratings being "buy" and one "strong buy." The average price target set by analysts is $13.25.
• The company's recent quarterly earnings report showed a loss of ($0.57) EPS, missing expectations, with revenues of $5.20 million, below analyst estimates of $9.50 million.
• Institutional investors currently hold 48.03% of Voyager Therapeutics' stock, indicating significant interest from larger investment entities.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned an average rating of "Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.2471.

A number of research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, September 15th. Wedbush dropped their target price on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th.

Voyager Therapeutics Price Performance

Shares of VYGR stock traded down $0.22 during trading hours on Thursday, reaching $4.27. The company had a trading volume of 915,232 shares, compared to its average volume of 672,993. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $8.27. The business has a fifty day simple moving average of $3.56 and a 200-day simple moving average of $3.42. The company has a market cap of $236.86 million, a price-to-earnings ratio of -2.31 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. On average, equities research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently bought and sold shares of VYGR. Northern Trust Corp lifted its holdings in Voyager Therapeutics by 3.0% during the fourth quarter. Northern Trust Corp now owns 418,745 shares of the company's stock worth $2,374,000 after acquiring an additional 12,374 shares during the period. Man Group plc bought a new stake in Voyager Therapeutics during the fourth quarter worth $234,000. Wellington Management Group LLP lifted its holdings in Voyager Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 261,251 shares of the company's stock worth $1,481,000 after acquiring an additional 31,882 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Voyager Therapeutics by 53.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock worth $204,000 after acquiring an additional 21,149 shares during the period. Finally, CWM LLC lifted its holdings in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after acquiring an additional 9,376 shares during the period. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.